vinorelbine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
vinca alkaloids	2827	71486-22-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: vinorelbin ditartrate noranhydrovinblastine tartrate vinorelbine navelbin navelbine base 5'-anhydrovinblastine vinorelbine tartrate vinorelbine ditartrate navelbine vinorelbine base	A vinca alkaloid related to VINBLASTINE that is used as a first-line treatment for NON-SMALL CELL LUNG CANCER, or for advanced or metastatic BREAST CANCER refractory to treatment with ANTHRACYCLINES. Molecular weight: 778.95 Formula: C45H54N4O8 CLOGP: 5.94 LIPINSKI: 3 HAC: 12 HDO: 2 TPSA: 133.87 ALOGS: -4.81 ROTB: 10 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

vinorelbin ditartrate
noranhydrovinblastine tartrate
vinorelbine
navelbin
navelbine base
5'-anhydrovinblastine
vinorelbine tartrate
vinorelbine ditartrate
navelbine
vinorelbine base

A vinca alkaloid related to VINBLASTINE that is used as a first-line treatment for NON-SMALL CELL LUNG CANCER, or for advanced or metastatic BREAST CANCER refractory to treatment with ANTHRACYCLINES.

Molecular weight: 778.95
Formula: C45H54N4O8
CLOGP: 5.94
LIPINSKI: 3
HAC: 12
HDO: 2
TPSA: 133.87
ALOGS: -4.81
ROTB: 10

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	1.00 mg/mL	Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine)	11 %	Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability)	27 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	23 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	20 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.87 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	26 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 23, 1994	FDA	PIERRE FABRE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	795.21	21.92	397	15844	81724	63391057
Disease progression	723.70	21.92	427	15814	122331	63350450
Metastases to liver	444.61	21.92	182	16059	23457	63449324
Metastases to bone	412.98	21.92	167	16074	20852	63451929
Neutropenia	407.08	21.92	345	15896	174660	63298121
Palmar-plantar erythrodysaesthesia syndrome	306.91	21.92	139	16102	22876	63449905
Metastases to lung	270.09	21.92	107	16134	12643	63460138
Metastases to lymph nodes	243.58	21.92	88	16153	8070	63464711
Neoplasm progression	235.70	21.92	135	16106	36293	63436488
Mucosal inflammation	213.94	21.92	139	16102	46789	63425992
Breast cancer metastatic	207.12	21.92	87	16154	11931	63460850
Metastases to central nervous system	190.13	21.92	84	16157	13021	63459760
Neuropathy peripheral	156.35	21.92	168	16073	113499	63359282
Metastases to peritoneum	121.26	21.92	42	16199	3400	63469381
Febrile neutropenia	119.06	21.92	149	16092	118300	63354481
PIK3CA-activated mutation	116.24	21.92	31	16210	1028	63471753
Breast cancer recurrent	104.52	21.92	40	16201	4301	63468480
Osteonecrosis of jaw	101.88	21.92	79	16162	35044	63437737
Pleural effusion	101.31	21.92	122	16119	93088	63379693
Ejection fraction decreased	98.88	21.92	65	16176	22267	63450514
Myelosuppression	97.74	21.92	66	16175	23637	63449144
Metastases to skin	93.89	21.92	29	16212	1634	63471147
Haematotoxicity	92.33	21.92	46	16195	9330	63463451
Thrombocytopenia	88.34	21.92	147	16094	151010	63321771
Ascites	85.57	21.92	76	16165	40652	63432129
Tonsillar disorder	81.89	21.92	24	16217	1129	63471652
Breast cancer	81.81	21.92	80	16161	48303	63424478
Blood uric acid decreased	71.84	21.92	20	16221	781	63472000
Neurotoxicity	69.30	21.92	47	16194	16943	63455838
Polyneuropathy	68.34	21.92	44	16197	14545	63458236
Eosinophil percentage increased	66.89	21.92	20	16221	1009	63471772
Fall	63.12	21.92	12	16229	392322	63080459
Nasal disorder	60.49	21.92	24	16217	2840	63469941
Off label use	59.30	21.92	333	15908	674129	62798652
Death	59.22	21.92	220	16021	374161	63098620
Cardiotoxicity	59.18	21.92	33	16208	8405	63464376
Bone marrow failure	58.24	21.92	53	16188	29237	63443544
Drug hypersensitivity	55.63	21.92	7	16234	310680	63162101
EGFR gene mutation	53.93	21.92	13	16228	284	63472497
Joint swelling	52.73	21.92	10	16231	327656	63145125
Hyperchlorhydria	51.70	21.92	19	16222	1825	63470956
Neutropenic sepsis	49.89	21.92	38	16203	16400	63456381
Therapy partial responder	47.11	21.92	31	16210	10627	63462154
Folate deficiency	46.27	21.92	19	16222	2456	63470325
Osteonecrosis	44.16	21.92	42	16199	24488	63448293
Skin toxicity	43.10	21.92	22	16219	4692	63468089
Disease recurrence	43.04	21.92	44	16197	27986	63444795
Acquired gene mutation	42.53	21.92	14	16227	969	63471812
Tumour marker increased	42.24	21.92	22	16219	4893	63467888
Arthralgia	41.47	21.92	51	16190	569659	62903122
Hiccups	41.28	21.92	17	16224	2214	63470567
Hepatotoxicity	41.04	21.92	49	16192	36992	63435789
Decreased appetite	40.84	21.92	149	16092	250903	63221878
Abdominal discomfort	40.06	21.92	16	16225	320869	63151912
Second primary malignancy	39.77	21.92	25	16216	7928	63464853
Vessel puncture site bruise	39.28	21.92	11	16230	439	63472342
Peripheral sensory neuropathy	38.71	21.92	24	16217	7427	63465354
Leukopenia	38.35	21.92	70	16171	77220	63395561
Diffuse large B-cell lymphoma recurrent	37.31	21.92	16	16225	2304	63470477
Lymphangiosis carcinomatosa	37.26	21.92	14	16227	1431	63471350
Blood creatinine decreased	37.02	21.92	21	16220	5524	63467257
Maternal exposure during pregnancy	36.94	21.92	6	16235	220056	63252725
Metastases to pleura	36.00	21.92	14	16227	1571	63471210
Joint neoplasm	34.80	21.92	7	16234	63	63472718
Diarrhoea	34.79	21.92	306	15935	715060	62757721
Superior vena cava syndrome	34.50	21.92	11	16230	688	63472093
Sinusitis	34.21	21.92	8	16233	226645	63246136
Mediastinum neoplasm	34.13	21.92	7	16234	70	63472711
Soft tissue neoplasm	33.96	21.92	7	16234	72	63472709
Hypothalamo-pituitary disorder	33.69	21.92	11	16230	742	63472039
Odynophagia	33.64	21.92	22	16219	7464	63465317
Metastatic neoplasm	33.44	21.92	18	16223	4277	63468504
Blood lactate dehydrogenase increased	33.18	21.92	35	16206	23081	63449700
Gastrointestinal toxicity	32.97	21.92	22	16219	7719	63465062
Transaminases	32.89	21.92	7	16234	85	63472696
Nail infection	32.84	21.92	15	16226	2508	63470273
Injection site extravasation	32.62	21.92	23	16218	8818	63463963
Nausea	32.47	21.92	347	15894	854124	62618657
Metastases to meninges	32.40	21.92	15	16226	2587	63470194
Metastases to spine	32.16	21.92	16	16225	3233	63469548
Metastases to chest wall	32.04	21.92	10	16231	583	63472198
Constipation	32.03	21.92	128	16113	224815	63247966
Pancytopenia	31.78	21.92	74	16167	96859	63375922
Urticaria	31.52	21.92	3	16238	165799	63306982
Condition aggravated	31.39	21.92	34	16207	402183	63070598
Pituitary tumour	31.21	21.92	11	16230	937	63471844
Musculoskeletal stiffness	31.05	21.92	5	16236	184613	63288168
Osteolysis	30.98	21.92	15	16226	2859	63469922
Hepatic enzyme increased	30.81	21.92	7	16234	202321	63270460
Metastasis	30.24	21.92	18	16223	5179	63467602
Drug resistance	29.89	21.92	33	16208	22900	63449881
Anaemia	29.79	21.92	151	16090	293279	63179502
Pruritus	28.82	21.92	30	16211	361423	63111358
Hormone receptor positive breast cancer	28.67	21.92	9	16232	535	63472246
Gene mutation	28.49	21.92	12	16229	1653	63471128
Jaw operation	28.48	21.92	10	16231	842	63471939
Nail avulsion	27.59	21.92	7	16234	190	63472591
Asthenia	27.54	21.92	180	16061	383424	63089357
Non-small cell lung cancer recurrent	27.02	21.92	6	16235	90	63472691
Carbohydrate antigen 15-3 increased	26.68	21.92	11	16230	1437	63471344
Gingival bleeding	25.45	21.92	23	16218	12564	63460217
Weight increased	25.21	21.92	18	16223	260774	63212007
Lymphoedema	24.90	21.92	22	16219	11670	63461111
Stress cardiomyopathy	24.69	21.92	20	16221	9430	63463351
Cardiac cirrhosis	24.68	21.92	6	16235	136	63472645
Poor peripheral circulation	24.50	21.92	14	16227	3735	63469046
Exposure during pregnancy	24.46	21.92	5	16236	155542	63317239
Pneumonitis	24.30	21.92	37	16204	35185	63437596
Dermatitis exfoliative generalised	24.30	21.92	14	16227	3793	63468988
Scintillating scotoma	24.12	21.92	6	16235	150	63472631
Toothache	23.94	21.92	27	16214	19172	63453609
Stomatitis	23.94	21.92	84	16157	138641	63334140
Mediastinal disorder	23.20	21.92	7	16234	364	63472417
Discomfort	23.18	21.92	7	16234	167367	63305414
Postictal state	22.94	21.92	9	16232	1034	63471747
Nail disorder	22.88	21.92	22	16219	12993	63459788
Vascular device infection	22.40	21.92	17	16224	7295	63465486
Eosinophil count increased	22.16	21.92	20	16221	10908	63461873
Somnolence	22.13	21.92	9	16232	178676	63294105

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neutropenia	128.23	26.58	121	3918	156657	34796235
Disease progression	121.49	26.58	100	3939	107977	34844915
Febrile neutropenia	84.78	26.58	91	3948	136758	34816134
Malignant neoplasm progression	69.87	26.58	67	3972	87979	34864913
Off label use	59.11	26.58	141	3898	419383	34533509
Neutropenic sepsis	56.88	26.58	29	4010	13738	34939154
Febrile bone marrow aplasia	54.56	26.58	24	4015	8185	34944707
Pneumonitis	50.16	26.58	37	4002	33841	34919051
Neoplasm progression	40.34	26.58	28	4011	23272	34929620
Thrombocytopenia	39.21	26.58	67	3972	156180	34796712
Leukopenia	39.12	26.58	42	3997	62814	34890078
Toxic erythema of chemotherapy	37.93	26.58	7	4032	92	34952800
Myelosuppression	37.76	26.58	25	4014	19240	34933652
Metastases to lung	33.81	26.58	18	4021	9302	34943590
Product leakage	30.61	26.58	8	4031	552	34952340
Interstitial lung disease	29.49	26.58	37	4002	65245	34887647
Bone marrow failure	28.46	26.58	25	4014	29228	34923664
Diffuse large B-cell lymphoma refractory	28.23	26.58	9	4030	1257	34951635
Pancytopenia	28.15	26.58	44	3995	95113	34857779
Product use in unapproved indication	27.62	26.58	49	3990	117450	34835442
Haematotoxicity	27.41	26.58	15	4024	8179	34944713

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	546.32	20.81	341	15876	135649	79592522
Disease progression	472.36	20.81	350	15867	184012	79544159
Neutropenia	366.50	20.81	366	15851	287344	79440827
Metastases to bone	254.83	20.81	116	16101	24311	79703860
Metastases to liver	229.49	20.81	113	16104	28201	79699970
Metastases to lung	227.25	20.81	98	16119	18065	79710106
Neoplasm progression	223.20	20.81	136	16081	51546	79676625
Palmar-plantar erythrodysaesthesia syndrome	171.36	20.81	98	16119	33036	79695135
Breast cancer metastatic	168.25	20.81	64	16153	8538	79719633
Mucosal inflammation	167.64	20.81	132	16085	75448	79652723
Metastases to lymph nodes	166.79	20.81	67	16150	10330	79717841
Febrile neutropenia	137.44	20.81	200	16017	230799	79497372
Neuropathy peripheral	137.14	20.81	156	16061	141149	79587022
Myelosuppression	126.92	20.81	87	16130	40209	79687962
Metastases to central nervous system	119.81	20.81	61	16156	16314	79711857
Neutropenic sepsis	111.11	20.81	69	16148	26995	79701176
Breast cancer recurrent	99.58	20.81	33	16184	2944	79725227
Metastases to peritoneum	90.82	20.81	34	16183	4338	79723833
Osteonecrosis of jaw	88.33	20.81	72	16145	43154	79685017
Haematotoxicity	85.87	20.81	48	16169	15471	79712700
Tonsillar disorder	85.11	20.81	24	16193	1242	79726929
Thrombocytopenia	82.99	20.81	173	16044	265086	79463085
Bone marrow failure	77.87	20.81	72	16145	51035	79677136
PIK3CA-activated mutation	76.95	20.81	19	16198	584	79727587
Metastases to skin	73.39	20.81	23	16194	1716	79726455
Ejection fraction decreased	71.49	20.81	58	16159	34519	79693652
EGFR gene mutation	66.23	20.81	16	16201	448	79727723
Blood uric acid decreased	62.67	20.81	19	16198	1269	79726902
Pneumonitis	62.04	20.81	69	16148	60791	79667380
Febrile bone marrow aplasia	60.64	20.81	36	16181	12984	79715187
Eosinophil percentage increased	59.60	20.81	19	16198	1499	79726672
Off label use	59.46	20.81	350	15867	906865	78821306
Nasal disorder	59.44	20.81	24	16193	3745	79724426
Therapy partial responder	55.79	20.81	38	16179	17359	79710812
Pancytopenia	50.47	20.81	107	16110	165638	79562533
Hyperchlorhydria	49.96	20.81	18	16199	2061	79726110
Fall	48.97	20.81	19	16198	487610	79240561
Neurotoxicity	46.04	20.81	44	16173	32474	79695697
Pleural effusion	45.64	20.81	95	16122	145167	79583004
Folate deficiency	41.57	20.81	18	16199	3342	79724829
Peripheral sensory neuropathy	40.68	20.81	28	16189	13005	79715166
Polyneuropathy	40.65	20.81	36	16181	24115	79704056
Vessel puncture site bruise	40.37	20.81	11	16206	501	79727670
Disease recurrence	39.86	20.81	47	16170	44062	79684109
Acquired gene mutation	37.92	20.81	15	16202	2218	79725953
Leukopenia	37.53	20.81	77	16140	116436	79611735
Metastases to spine	37.23	20.81	18	16199	4306	79723865
Arthralgia	37.11	20.81	37	16180	571766	79156405
Nail infection	36.88	20.81	15	16202	2384	79725787
Drug hypersensitivity	36.65	20.81	8	16209	298908	79429263
Joint neoplasm	36.40	20.81	7	16210	63	79728108
Ascites	35.80	20.81	59	16158	75503	79652668
Nausea	35.74	20.81	323	15894	956873	78771298
Hepatotoxicity	35.70	20.81	48	16169	51304	79676867
Breast cancer	35.62	20.81	39	16178	33742	79694429
Cardiotoxicity	35.18	20.81	25	16192	12214	79715957
Soft tissue neoplasm	34.49	20.81	7	16210	85	79728086
Hormone receptor positive breast cancer	34.21	20.81	9	16208	358	79727813
Gastrointestinal toxicity	34.09	20.81	21	16196	8088	79720083
Blood creatinine decreased	32.23	20.81	20	16197	7805	79720366
Non-small cell lung cancer recurrent	32.19	20.81	7	16210	121	79728050
Nail avulsion	31.72	20.81	7	16210	130	79728041
Lymphangiosis carcinomatosa	31.52	20.81	13	16204	2141	79726030
Hypothalamo-pituitary disorder	31.19	20.81	11	16206	1183	79726988
Agranulocytosis	31.16	20.81	42	16175	44988	79683183
Pituitary tumour	30.94	20.81	11	16206	1211	79726960
Blood lactate dehydrogenase increased	30.94	20.81	39	16178	39131	79689040
Injection site extravasation	30.71	20.81	21	16196	9648	79718523
Odynophagia	29.96	20.81	22	16195	11305	79716866
Acute myeloid leukaemia	29.73	20.81	34	16183	30851	79697320
Metastases to the mediastinum	29.69	20.81	9	16208	601	79727570
Joint swelling	29.35	20.81	11	16206	288635	79439536
Transaminases	29.26	20.81	6	16211	77	79728094
Metastatic neoplasm	28.99	20.81	16	16201	5026	79723145
Gene mutation	28.76	20.81	13	16204	2673	79725498
Drug resistance	28.64	20.81	39	16178	42174	79685997
Mediastinum neoplasm	28.33	20.81	6	16211	91	79728080
Constipation	28.09	20.81	123	16094	282927	79445244
Primary mediastinal large B-cell lymphoma	27.93	20.81	5	16212	29	79728142
Poor peripheral circulation	27.75	20.81	14	16203	3669	79724502
Toxic erythema of chemotherapy	27.39	20.81	7	16210	248	79727923
Anaemia	27.24	20.81	169	16048	444846	79283325
Jaw operation	26.97	20.81	9	16208	820	79727351
Diarrhoea	26.87	20.81	285	15932	880204	78847967
Gingival bleeding	26.87	20.81	24	16193	16252	79711919
Decreased appetite	26.86	20.81	139	16078	342279	79385892
Osteonecrosis	26.23	20.81	32	16185	31063	79697108
Stress cardiomyopathy	25.79	20.81	20	16197	11146	79717025
Tumour marker increased	25.79	20.81	14	16203	4258	79723913
Product use in unapproved indication	25.76	20.81	110	16107	250249	79477922
Asthenia	25.71	20.81	185	16032	511504	79216667
Urticaria	24.73	20.81	4	16213	185197	79542974
Skin toxicity	23.94	20.81	17	16200	8297	79719874
Scintillating scotoma	23.52	20.81	6	16211	211	79727960
Cough	23.51	20.81	141	16076	366648	79361523
Cardiac cirrhosis	23.25	20.81	6	16211	221	79727950
Abdominal discomfort	23.17	20.81	11	16206	250716	79477455
Therapeutic product effect decreased	23.13	20.81	3	16214	163860	79564311
Hypotension	22.72	20.81	34	16183	440283	79287888
Toothache	22.71	20.81	24	16193	19946	79708225
Nail disorder	22.65	20.81	19	16198	11833	79716338
Toxicity to various agents	22.28	20.81	32	16185	421508	79306663
Stomatitis	22.20	20.81	73	16144	146684	79581487
Pneumothorax	22.05	20.81	28	16189	28295	79699876
Condition aggravated	21.91	20.81	43	16174	501081	79227090
Invasive ductal breast carcinoma	21.62	20.81	14	16203	5878	79722293
Tumour pain	21.10	20.81	10	16207	2289	79725882
Hiccups	21.09	20.81	17	16200	10014	79718157
Vaginal discharge	20.89	20.81	15	16202	7448	79720723

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01CA04	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS Vinca alkaloids and analogues
FDA CS	M0022674	Vinca Alkaloids
MeSH PA	D050256	Antimitotic Agents
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D000972	Antineoplastic Agents, Phytogenic
MeSH PA	D050257	Tubulin Modulators
FDA EPC	N0000175612	Vinca Alkaloid
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:47868	photosensitising agent

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Non-small cell lung cancer	indication	254637007	DOID:3908
Kaposi's sarcoma	off-label use	109385007
Neoplasm of endometrium	off-label use	123844007	DOID:1380
Small cell carcinoma of lung	off-label use	254632001	DOID:5409
Metastatic Breast Carcinoma	off-label use
Disorder of lung	contraindication	19829001	DOID:850
Infectious disease	contraindication	40733004
Gastrointestinal perforation	contraindication	51875005
Hepatic failure	contraindication	59927004
Interstitial pneumonia	contraindication	64667001
Intestinal obstruction	contraindication	81060008	DOID:8437
Leukopenia	contraindication	84828003	DOID:615
Gastrointestinal obstruction	contraindication	126765001
Pregnancy, function	contraindication	289908002
Bone marrow depression	contraindication	307762000
Breastfeeding (mother)	contraindication	413712001
Hepatic Metastases	contraindication
Intestinal Ischemic Necrosis	contraindication
Severe Granulocytopenia	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.32	acidic
pKa2	13.35	acidic
pKa3	8.55	Basic
pKa4	7.39	Basic
pKa5	6.11	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Tubulin beta	Tumour-associated antigen	P07437 Q9H4B7 Q13885 Q9BVA1 Q13509 P04350 P68371 Q9BUF5 Q3ZCM7	TBB5_HUMAN TBB1_HUMAN TBB2A_HUMAN TBB2B_HUMAN TBB3_HUMAN TBB4A_HUMAN TBB4B_HUMAN TBB6_HUMAN TBB8_HUMAN	INHIBITOR			SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Cytochrome P450 3A4	Enzyme	P08684	CP3A4_HUMAN		IC50	6	DRUG MATRIX
Substance-K receptor	GPCR	P21452	NK2R_HUMAN		Ki	6.27	DRUG MATRIX

External reference:

ID	Source
4023981	VUID
N0000021986	NUI
D01935	KEGG_DRUG
125317-39-7	SECONDARY_CAS_RN
4020895	VANDF
4023981	VANDF
C0078257	UMLSCUI
CHEBI:480999	CHEBI
GDF	PDB_CHEM_ID
CHEMBL553025	ChEMBL_ID
CHEMBL538943	ChEMBL_ID
CHEMBL3039595	ChEMBL_ID
D000077235	MESH_DESCRIPTOR_UI
DB00361	DRUGBANK_ID
7105	IUPHAR_LIGAND_ID
6054	INN_ID
Q6C979R91Y	UNII
5311497	PUBCHEM_CID
114527	RXNORM
2135	MMSL
46388	MMSL
5676	MMSL
d03810	MMSL
004380	NDDF
004381	NDDF
108792008	SNOMEDCT_US
108794009	SNOMEDCT_US
372541004	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Vinorelbine	HUMAN PRESCRIPTION DRUG LABEL	1	25021-204	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	27 sections
Vinorelbine	HUMAN PRESCRIPTION DRUG LABEL	1	45963-607	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	19 sections
Vinorelbine	HUMAN PRESCRIPTION DRUG LABEL	1	45963-607	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	19 sections
Vinorelbine	HUMAN PRESCRIPTION DRUG LABEL	1	45963-607	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	19 sections